News

News 2016-10-15T14:05:37+00:00
610, 2017

VLP Therapeutics Announces Phase 1 SBIR Grant Award From National Cancer Institute

2017.10.06|

VLP Therapeutics Announces Phase 1 SBIR Grant Award From National Cancer Institute Grant will support development of novel Virus-Like Particle vaccine-based cancer immunotherapy October 6, 2017 Gaithersburg, MD – VLP

2107, 2017

VLP Therapeutics Appoints Jacob Licht as Chief Operating Officer

2017.07.21|

Gaithersburg, Md. — July 21, 2017 — VLP Therapeutics, LLC (“VLP”), a biotechnology company focusing on the research and development of therapeutic and preventative vaccines and antibody agents, today announced

107, 2017

Clinical and Vaccine Immunology – July 2017, Volume 24, Issue 7

2017.07.01|

“Development of a Novel Virus-Like Particle Vaccine Platform That Mimics the Immature Form of Alphavirus” Akane Urakami, Atsuko Sakurai, Momoko Ishikawa, Moh Lan Yap, Yevel Flores-Garcia, Yasunari Haseda, Taiki Aoshi,

905, 2017

VLP Therapeutics Announces Convertible Note Investment from TomyK Ltd. for Accelerating Cancer Vaccine Development

2017.05.09|

Gaithersburg, Md. — May 9, 2017 — VLP Therapeutics, LLC (“VLP”), a biotechnology company focusing on the research and development of therapeutic and preventative vaccines and antibody agents, today announced